Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Joseph M ConnorsB Zee

Abstract

This randomized, prospective trial compares outcomes for patients with advanced Hodgkin's disease treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/doxorubicin, bleomycin, and vinblastine (ABV) hybrid regimen or alternating MOPP/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Three hundred one patients with advanced Hodgkin's disease were randomized to receive MOPP/ ABV hybrid regimen or alternating MOPP/ABVD after stratification for prior treatment, B symptoms, and treatment center. Eligible patients were either previously untreated and found to have stage IIIB, IVA, or IVB disease or previously treated with wide-field irradiation. Responding patients received a minimum of eight cycles of chemotherapy. Those with residual disease in a localized region received irradiation between the sixth and seventh cycle of treatment. Response rates to the two regimens were similar. Five-year overall survival rates were 81% and 83% for MOPP/ABV hybrid and alternating MOPP/ ABVD, respectively (P = .74; 95% confidence interval [CI] for the difference, -11% to 7%). Five-year failure-free survivals were 71% and 67% for MOPP/ABV hybrid and alternating MOPP/ABVD, respectively (P = .87; 95% CI for the diff...Continue Reading

Citations

Sep 7, 2000·Journal of Clinical Pharmacology·J P DutcherP H Wiernik
Nov 28, 2001·Hematology·J M ConnorsS J Horning
Jun 13, 2003·The New England Journal of Medicine·Volker DiehlUNKNOWN German Hodgkin's Lymphoma Study Group
Aug 30, 2008·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Michinori Ogura
Apr 25, 2009·The Cancer Journal·Beate Klimm, Andreas Engert
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mubarak Al-MansourKerry J Savage
Mar 1, 2006·Current Hematologic Malignancy Reports·Beate KlimmVolker Diehl
Jul 24, 2010·Journal of Cancer Survivorship : Research and Practice·Shayna ZelcerFarid H Mahmud
Nov 6, 2010·Expert Opinion on Pharmacotherapy·Bharti Rathore, Marshall E Kadin
Jul 26, 2016·Experimental and Therapeutic Medicine·Yongzhi MenZiwei Yu
Apr 11, 2018·American Journal of Hematology·Stephen M Ansell
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra J HorningSaul A Rosenberg
Mar 2, 2002·European Journal of Haematology·T P VassilakopoulosG A Pangalis
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertUNKNOWN German Hodgkin's Study Group
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
May 24, 2006·BMC Public Health·Paul D JamesYang Mao
Apr 25, 2009·The Cancer Journal·Pamela SeamVincent T Devita
Jul 13, 2005·European Journal of Haematology. Supplementum·Beate KlimmAndreas Engert
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Aug 3, 2010·Annals of Hematology·Joanne NgeowSoon Thye Lim
Feb 19, 2008·British Journal of Haematology·Pauline Brice
Jun 24, 2014·American Journal of Hematology·Stephen M Ansell
Aug 4, 2015·Future Oncology·Wafa'a A Al-JizaniEzzeldin M Ibrahim
Mar 24, 2016·American Journal of Hematology·Stephen M Ansell
Sep 7, 2000·Current Opinion in Oncology·A JostingV Diehl
Nov 20, 2002·British Journal of Haematology·Ayad AtraUNKNOWN UKCCSG/Hodgkin's Disease Group
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Berthe M P AlemanFlora E van Leeuwen
Sep 4, 2003·Leukemia & Lymphoma·Agustin AvilésMartha González
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo G GobbiUNKNOWN Intergruppo Italiano Linfomi
Oct 28, 2015·American Journal of Hematology·Stephen M Ansell
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J HorningP Cassileth
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter W M JohnsonUNKNOWN United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michal SieniawskiAndreas Josting

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Simonetta VivianiP Valagussa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D L LongoV T DeVita
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D B DugganB A Peterson
© 2021 Meta ULC. All rights reserved